UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

27 Voices on Value: Breaking Down the Value Chain: The Policies Impacting Patients

Read More Share:

Apr

21 Earth Day 2023: Our Commitment to Sustainability in the Workplace

Read More Share:

Apr

20 UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting

Read More Share:

Apr

18 How Shared Decision-Making Creates Better Patient-Provider Collaboration in Dermatology

Read More Share:

Apr

17 UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

Read More Share:

Apr

14 Recognizing UCB’s Rising Stars: Brittany Blair and Lauren Drowley Recognized by the Healthcare Businesswomen’s Association

Read More Share:

Apr

13 UCB’s Commitment to Understanding Sudden Unexpected Death in Epilepsy (SUDEP)

Read More Share:

Mar

18 Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

Read More Share:

Mar

17 Exploring the future of dermatology at AAD 2023

Read More Share:

Mar

16 You Speak, We Listen: How Community Voices Drive Our Work in HS

Read More Share:

Categories

Archives

Apr

27

Voices on Value: Breaking Down the Value Chain: The Policies Impacting Patients

Apr

21

Earth Day 2023: Our Commitment to Sustainability in the Workplace

Apr

20

UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting

Apr

18

How Shared Decision-Making Creates Better Patient-Provider Collaboration in Dermatology

Apr

17

UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

Apr

14

Recognizing UCB’s Rising Stars: Brittany Blair and Lauren Drowley Recognized by the Healthcare Businesswomen’s Association

Apr

13

UCB’s Commitment to Understanding Sudden Unexpected Death in Epilepsy (SUDEP)

Mar

18

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

Mar

17

Exploring the future of dermatology at AAD 2023

Mar

16

You Speak, We Listen: How Community Voices Drive Our Work in HS

Choose Country

UCB in the U.S.

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Apr

27

Voices on Value: Breaking Down the Value Chain: The Policies Impacting Patients

Apr

21

Earth Day 2023: Our Commitment to Sustainability in the Workplace

Apr

20

UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting

Apr

18

How Shared Decision-Making Creates Better Patient-Provider Collaboration in Dermatology

Apr

17

UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

Apr

14

Recognizing UCB’s Rising Stars: Brittany Blair and Lauren Drowley Recognized by the Healthcare Businesswomen’s Association

Apr

13

UCB’s Commitment to Understanding Sudden Unexpected Death in Epilepsy (SUDEP)

Mar

18

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

Mar

17

Exploring the future of dermatology at AAD 2023

Mar

16

You Speak, We Listen: How Community Voices Drive Our Work in HS

Choose Country

UCB in the U.S.

Innovation

Disease Areas

UCB Worldwide

Sustainability

Newsroom

Contact